IN8bio (NASDAQ:INAB) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS

IN8bio (NASDAQ:INAB) announced its quarterly earnings data on Thursday. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03, Zacks reports.

IN8bio Stock Performance

Shares of NASDAQ INAB opened at $0.23 on Friday. The firm’s 50-day moving average price is $0.28 and its 200-day moving average price is $0.30. IN8bio has a 52-week low of $0.22 and a 52-week high of $1.74. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.05. The company has a market cap of $18.39 million, a PE ratio of -0.30 and a beta of 0.03.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of IN8bio in a research report on Wednesday, February 12th.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.